IN8bio Inc. (INAB)
NASDAQ: INAB
· Real-Time Price · USD
2.24
0.03 (1.36%)
At close: Jun 17, 2025, 10:30 AM
1.36% (1D)
| Bid | 2.13 |
| Market Cap | 7.71M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -27.43M |
| EPS (ttm) | -13.2 |
| PE Ratio (ttm) | -0.17 |
| Forward PE | -0.35 |
| Analyst | Buy |
| Ask | 2.32 |
| Volume | 24,181 |
| Avg. Volume (20D) | 143,414 |
| Open | 2.21 |
| Previous Close | 2.21 |
| Day's Range | 2.19 - 2.27 |
| 52-Week Range | 2.13 - 30.60 |
| Beta | 0.18 |
About INAB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol INAB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for INAB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
-0.81%
IN8bio shares are trading lower after the company ...
Unlock content with
Pro Subscription
1 month ago
-9.55%
IN8bio shares are trading lower. The company announced new preclinical data from its INB-619 program at the 2025 American Society of Gene & Cell Therapy Annual Meeting
2 years ago · proactiveinvestors.com
IN8bio stock price falls even as company receives FDA orphan drug status for brain cancer treatmentIN8bio (NASDAQ:INAB), Inc shares slid 16% to $2.51 in early Tuesday trading after the biopharmaceutical company announced that it has received orphan drug designation from the US Food and Drug Adminis...
